regdanvimab: Clinical Trials

4 trials of regdanvimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 unknown. 2 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Completed 1
Phase 31Completed 1
Phase 41Unknown 1

Follow regdanvimab: new trials by email Literature Review of regdanvimab trials Research Report on regdanvimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19
tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab - Coronavirus Infections
Phase 4UnknownCity Clinical Hospital No.52 of Moscow Healthcare Department822022-08-182023-08-08
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
CT-P59, Placebo - SARS-CoV-2 Infection
Phase 2 / Phase 3CompletedCelltrion16422020-10-052022-07-20
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
CT-P59 - SARS-CoV-2 Infection
Phase 1CompletedCelltrion182020-09-042022-04-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
CT-P59, Placebo - SARS-CoV-2 Infection
Phase 1CompletedCelltrion322020-07-182021-11-16

Conditions studied

COVID-19 (3)  ·  Coronavirus Infections (1)

Sponsors

Celltrion (3)  ·  City Clinical Hospital No.52 of Moscow Healthcare Department (1)

Countries

South Korea (3)  ·  Russia (1)

Results publications

PMID 34473343, PMID 34551869, PMID 35713300, PMID 35295819, PMID 36043180, PMID 37928549